Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test by year’s end.
May 26, 2026 06:57 AM EDT
R&DCell/Gene Tx
Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout
Reynald Castaneda
Deputy Editor
Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L
Pharmalittle: We're reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Immunovant shares surge on arthritis trial data
Five biotech news updates to stay on top of today
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology
Eli Lilly acquires Engage Biologics for up to $202 million
Repatha reduces CV events in patients who had PCI but no heart attack or stroke
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a…
Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of…
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects…
Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1…
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
